Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs
For years now Roche has dominated the very top circle of Big Pharma R&D, investing more than $8 billion a year in drug development through …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
